NUVB:NYE-Nuvation Bio Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3

Change

-0.18 (-5.66)%

Market Cap

USD 0.86B

Volume

1.92M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

-1.73 (-1.27%)

USD 612.29B
BHVN Biohaven Pharmaceutical Holdin..

-0.32 (-0.84%)

USD 3.61B
RCUS Arcus Biosciences Inc

-0.25 (-1.51%)

USD 1.58B
DNA Ginkgo Bioworks Holdings

+0.14 (+2.30%)

USD 0.39B
ADCT ADC Therapeutics SA

+0.05 (+1.83%)

USD 0.27B
CYBN Cybin Inc

-0.01 (-3.03%)

USD 0.20B
ANVS Annovis Bio Inc

+0.06 (+0.72%)

USD 0.11B
ARMP Armata Pharmaceuticals Inc

+0.08 (+3.13%)

USD 0.09B
MAIA MAIA Biotechnology Inc.

+0.46 (+15.75%)

USD 0.07B
PLX Protalix Biotherapeutics Inc

-0.06 (-5.61%)

USD 0.07B

ETFs Containing NUVB

CNCR Loncar Cancer Immunothera.. 2.06 % 0.79 %

-0.05 (-0.31%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 98.68% 88% B+ 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 98.68% 88% B+ 99% N/A
Trailing 12 Months  
Capital Gain 57.07% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.07% 90% A- 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.53% 19% F 3% F
Dividend Return -24.53% 19% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.43% 58% F 20% F
Risk Adjusted Return -54.00% 29% F 7% C-
Market Capitalization 0.86B 89% A- 52% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.